Obudai Egeszseguegyi Centrum Kft.

The research at Obudai Egeszseguegyi Centrum Kft. includes several studies aimed at reducing the risk of major heart events in patients with atherosclerotic cardiovascular disease and related conditions.

• Inclisiran to lower the incidence of major adverse cardiovascular events
• Maridebart Cafraglutide as an adjunct therapy for cardiovascular morbidity and mortality
• Olpasiran targeting lipoprotein(a) to prevent first major cardiovascular events
• AZD0780 evaluated for its impact on LDL‑C levels
• Baxdrostat combined with dapagliflozin to improve kidney‑cardio outcomes

These trials collectively explore innovative treatments to improve heart health and prevent complications such as heart attacks and strokes.

Studies at the centre focus on inflammatory bowel conditions, particularly ulcerative colitis, seeking therapies that promote mucosal healing and symptom relief.

• Obefazimod versus placebo for endoscopic improvement and remission
• ABTECT‑2 trial evaluating ABX464 in moderate to severe ulcerative colitis

The goal is to identify effective options that can achieve sustained disease control for patients with chronic digestive inflammation.

The site conducts research on neurological disorders such as migraine and agitation linked to Alzheimer’s disease, testing novel agents for symptom reduction.

• MEDI0618 repeat dosing to prevent episodic migraine headaches
• KarXT + KarX‑EC for agitation associated with Alzheimer’s disease

These investigations aim to provide safer, more effective ways to manage pain and behavioral symptoms that impact quality of life.

A dedicated trial evaluates advanced cell‑based therapy for patients with chronic, non‑healing venous leg ulcers, a condition that often resists conventional treatment.

• Topical allo‑APZ2‑CVU stem cell product compared with placebo for wound closure

The study’s purpose is to determine whether the investigational product can accelerate healing and reduce ulcer recurrence.

Research on mental disorders centers on agitation in Alzheimer’s disease, evaluating both safety and efficacy of a combined pharmacologic approach.

• Long‑term safety and tolerability of KarXT + KarX‑EC
• Efficacy measured by reduction in agitation scores using the CMAI‑IPA scale

These trials seek to offer clinicians new tools to manage behavioral challenges in dementia care.